On This Day in Health: March 14, 2024
On March 14, 2024, the United States Food and Drug Administration approved resmetirom, marketed as Rezdiffra, for adults with noncirrhotic nonalcoholic steatohepatitis and moderate to advanced liver scarring. The condition was widely abbreviated NASH in the announcement and is also described using the newer term metabolic dysfunction-associated steatohepatitis, or MASH. The decision supplied the first FDA-approved treatment for this defined patient population. It was intended to be used alongside diet and exercise, reflecting an approach that combined a medicine with the existing foundations of care rather than treating the approval as a substitute for them.
Fatty liver disease can progress from fat accumulation to inflammation and fibrosis, the process of scar tissue forming in the liver. Not everyone with liver fat develops the same degree of damage, so the new indication specified both the disease and the extent of scarring. Resmetirom acts through a thyroid hormone receptor pathway in the liver, helping reduce liver fat. The American Liver Foundation welcomed the authorization as a milestone for patients and research. Its significance was tied to a previously unmet treatment need, while the limits of the indication made clear that the approval did not encompass every form or stage of liver disease.
The FDA used its accelerated approval pathway, relying on changes in liver inflammation and scarring as surrogate endpoints reasonably likely to predict clinical benefit. An analysis of 888 participants compared two treatment doses with placebo, all alongside standard care. Liver biopsies after twelve months showed improvement in a greater proportion of treated participants. These findings supported earlier access, but they did not settle every question about long-term outcomes. The regulator required continued study to verify and describe clinical benefit. That distinction between a biopsy-based measure and later health outcomes is essential to understanding what the approval established at the time and what further research was expected to determine.
The authorization also carried a need to assess tolerability and possible complications. Diarrhea and nausea were common adverse effects, while prescribing information addressed liver toxicity, gallbladder problems, and drug interactions. March 14 therefore marks the arrival of a treatment option with defined conditions for its use and continuing obligations for evidence development. The broader story is one of translating knowledge about liver biology into a medicine and then testing whether measurable changes can lead to meaningful health benefits. For patients and clinicians, the milestone expanded available care without closing the research agenda. It shows how progress in a slowly developing disease can involve both an immediate regulatory decision and years of follow-up needed to understand its lasting consequences.
The approval covered noncirrhotic disease with moderate to advanced scarring. It was not an authorization for every fatty liver condition.
Resmetirom was intended alongside diet and exercise. The medicine expanded an existing approach to care.
Accelerated approval relied on liver-biopsy measures. Longer-term clinical benefit still required verification.
The study compared two doses with placebo alongside standard care. More treated participants met the specified biopsy endpoints.
The NASH terminology in the announcement overlaps with the newer MASH name. The anniversary concerns the 2024 decision and its defined population.
A first treatment can change available care while leaving questions open. Continued research and practical monitoring remained part of the milestone.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.